Novavax Global Commercial Operations and COVID-19 Vaccine Update

Local solicited symptoms similar across study groups after boost Boost dose administered median 6 Months after 3 doses mRNA 100% 80% 60% 40% 20% 100% 0% BA.1 Prototype Pain/Tenderness Bivalent All grades Grades 3+ Swelling Erythema 80% 60% 40% 20% 0% Fatigue* Headache Muscle pain Joint pain N/V novavax Fever © 2023 NOVAVAX. All rights reserved. 57 NK

View entire presentation